These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33808631)

  • 1. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer.
    Zhu G; Ren D; Lei X; Shi R; Zhu S; Zhou N; Zu L; Mello RA; Chen J; Xu S
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
    Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
    Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Kim H; Kwon HJ; Kim ES; Kwon S; Suh KJ; Kim SH; Kim YJ; Lee JS; Chung JH
    Cancer Res Treat; 2022 Apr; 54(2):424-433. PubMed ID: 34237208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in
    Liu D; Benzaquen J; Morris LGT; Ilié M; Hofman P
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations.
    Ma T; Jiao J; Huo R; Li X; Fang G; Zhao Q; Liu W; Han X; Xi C; Wang Y; Shang Y
    Front Oncol; 2022; 12():922899. PubMed ID: 35992815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1647-1654. PubMed ID: 32342665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
    Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
    Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models.
    Shi S; Wang Y; Wu J; Zha B; Li P; Liu Y; Yang Y; Kong J; Gao S; Cui H; Huangfu L; Sun X; Li Z; Liang T; Zheng Y; Yang D
    Front Oncol; 2024; 14():1342262. PubMed ID: 38756661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.
    Zhao J; Wang L; Zhou A; Wen S; Fang W; Zhang L; Duan J; Bai H; Zhong J; Wan R; Sun B; Zhuang W; Lin Y; He D; Cui L; Wang Z; Wang J
    Med; 2024 May; ():. PubMed ID: 38781965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
    Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
    Hwang S; Kwon AY; Jeong JY; Kim S; Kang H; Park J; Kim JH; Han OJ; Lim SM; An HJ
    Sci Rep; 2020 Jan; 10(1):643. PubMed ID: 31959763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
    Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
    J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.